In fact, clinical trials have explored the potential of CCR2/5-inhibitors, such as BMS-813160, in combination with neoadjuvant nivolumab for non-small cell lung cancer or liver cancer, currently in a phase II trial (NCT04123379) 53. This evidence concerns the gene CCR2 and non-small cell lung carcinoma.